E. Gouzoulis-Mayfrank

Publications147
h-index39
Citations4,114
Highly Influential Citations269
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Parrott
  • 212 Publications • 8,444 Citations
  • M. Geyer
  • 651 Publications • 48,048 Citations
  • G. Ricaurte
  • 200 Publications • 16,135 Citations
  • J. Daumann
  • 33 Publications • 1,486 Citations
  • Publications
  • Influence
Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users
View on Elsevier
The role of cannabis in cognitive functioning of patients with schizophrenia
TLDR
In the view of this study, the better cognitive functioning of SCH + CUD patients may rather reflect a relatively lower vulnerability to psychosis compared to the SCH group, which may correspond to a higher level of functioning such as cognitive ability.
View on Springer
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
TLDR
The present study suggests that the NMDA antagonist model of psychosis is not overall superior to the serotonin 5-HT2A agonist model, and the two classes of drugs tend to model different aspects or types of schizophrenia.
View on PubMed
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
TLDR
The data suggest that even typical recreational doses of ecstasy are sufficient to cause neurotoxicity in humans, and raise concern that use of ecstasy possibly in conjunction with cannabis may lead to cognitive decline in otherwise healthy young people.
View on PubMed
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind…
TLDR
The view that entactogens constitute a distinct psychoactive substance class taking an intermediate position between hallucinogens and stimulants is supported, and is in line with both users’ reports and results from previous experimental studies.
View on Springer
Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG
View on Nature
High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users
View on Springer
The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview
The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several…
View on SAGE
Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal…
TLDR
The present findings suggest that self-reported psychopathology in ecstasy users is predominantly attributable to concomitant use of cannabis, and abstinence from cannabis and not ecstasy seems to be a reliable predictor for remission of psychological complaints instasy users.
View on Springer
Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study.
View on PubMed
...
...